Hangzhou DAC Biotech Co.
Latest round
- Series C
Last raised
- May 2021
Total raised
- $162M
Investors
- 14
About Hangzhou DAC Biotech Co.
, Ltd is a biotechnology company that engages in the research and development of conjugate of monoclonal antibody and small molecular cytotoxic drug. The company’s core technical team includes 5 overseas returnees, 36 domestically graduated doctors and masters, and more than 40 bachelor’s degree professional and technical personnel. The company mainly develops antibody-drug conjugates, including tubulin inhibitors, DNA groove inhibitors, DNA alkylation and RNA polymerase inhibitors. It targets tumor cells through antibodies, and releases cytotoxic drugs through chemical or enzymatic action at the tumor to achieve precise killing of tumor cells.
Who invested in Hangzhou DAC Biotech Co.
14 investors across 4 rounds
See all investors in Hangzhou DAC Biotech Co.
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Questions about Hangzhou DAC Biotech Co.
Who invested in Hangzhou DAC Biotech Co.?
Hangzhou DAC Biotech Co. has 14 investors on record across 4 venture rounds. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has Hangzhou DAC Biotech Co. raised?
Hangzhou DAC Biotech Co. has raised 4 venture rounds. Sign up free to see how much each round raised and the total.
When did Hangzhou DAC Biotech Co. last raise money?
Hangzhou DAC Biotech Co.'s most recent round on record is a Series C, in May 2021.
What does Hangzhou DAC Biotech Co. do?
, Ltd is a biotechnology company that engages in the research and development of conjugate of monoclonal antibody and small molecular cytotoxic drug.
Where is Hangzhou DAC Biotech Co. headquartered?
Hangzhou DAC Biotech Co. is headquartered in Hangzhou, China.
Which VCs invest in companies like Hangzhou DAC Biotech Co.?
Among active investors with capital left to deploy, Shanghai State-owned Capital Investment Leading Fund, Hui Hua Fund, Yufu Capital and ICBC Capital Management back pharmaceuticals companies at Hangzhou DAC Biotech Co.'s stage. Their profiles are linked below.
VCs backing pharmaceuticals startups at Series C
Raising like Hangzhou DAC Biotech Co.? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.